https://fshd-russia.ru/zavershen-nabor-v-tretyu-fazu-issledovaniya-losmapimoda-pri-myshechnoj-distrofii-landuzi-dezherina/2024-07-21T13:21:27+00:00https://fshd-russia.ru/issledovanie-preparata-aro-dux4-na-vzroslyh-paczientov-s-pleche-lopatochno-liczevoj-myshechnoj-distrofiej-landuzi-dezherina-1-go-tipa/2024-03-07T08:11:10+00:00https://fshd-russia.ru/celularity-podala-zayavku-v-upravlenie-po-kontrolyu-kachestva-pishhevyh-produktov-i-lekarstvennyh-preparatov-ssha-na-prisvoenie-statusa-orfannogo-preparata-preparatu-pda-002-dlya-lecheniya-pleche-lopa/2024-03-22T11:30:30+00:00https://fshd-russia.ru/kompaniya-fulcrum-therapeutics-zaklyuchila-liczenzionnoe-soglashenie-o-sotrudnichestve-s-sanofi-dlya-razrabotki-i-kommerczializaczii-preparata-losmapimod-dlya-lecheniya-licze-lopatochno-plechevoj-mysh/2024-07-21T13:20:35+00:00https://fshd-russia.ru/kompaniya-avidity-obyavlyaet-bespreczedentnye-dannye-aoc-1020-iz-issledovaniya-1-2-fazy-fortitude-demonstriruyushhie-bolee-chem-50-proczentnoe-snizhenie-kolichestva-genov-reguliruemyh-dux4/2024-07-07T14:09:02+00:00https://fshd-russia.ru/fulcrum-therapeutics-obyavlyaet-osnovnye-rezultaty-klinicheskogo-issledovaniya-fazy-3-preparata-losmapimod-pri-licze-lopatochno-plechevoj-myshechnoj-distrofii-llpmd/2024-10-11T19:41:06+00:00